Revolution Medicines to acquire EQRx in deal that will add $1 billion in cash to its balance sheet to fund R&D
Revolution Medicines Inc. (RVMD) said Tuesday it has reached a definitive agreement to acquire EQRx Inc. (EQRX) in an all-cash deal that's expected to add more than $1 billion in net cash to its balance sheet. Revolution Medicines specializes in therapies for RAS-addicted cancers, or those that are caused by mutations in RAS genes. The company is expecting to use the proceeds of the $1 billion to fund late-stage development of RAS inhibitor drug candidates. Under the terms of the board-approved deal, EQRx shareholders will receive shares to be determined closer to the shareholder vote on the deal using an exchange-ratio formula equal to about 7.7 million Revolution shares as well as shares equal to $870 million that will be discounted based on Revolution's share price at that time. "This singular acquisition of a sizable quantum of capital signifies the growing confidence we have in our RAS-focused drug candidate pipeline, and substantially increases our capacity to continue advancing high-performing oncology assets, particularly our priority clinical-stage RAS(ON) Inhibitors, RMC-6236, RMC-6291 and RMC-9805, with the potential to create significant long-term value for our shareholders," said REvolution's CEO Dr. Mark A. Goldsmith in a statement. The deal is expected to close in November.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-01-23 0758ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?